| Linagliptin,patients with events/total patients | Total comparators,patients with events/total patients | Cox HR (95% CI) | Incidence ratio (95% CI) CMH Test |
---|---|---|---|---|
Age (years) | ||||
≤50 | 5/1288 | 3/781 | 1.31 (0.31–5.58) | 1.11 (0.47–2.63) |
51 to <65 | 26/2817 | 26/1740 | 0.75 (0.43–1.30) | 0.86 (0.52–1.41) |
65 to 75 | 26/1418 | 29/902 | 0.78 (0.46–1.32) | 0.84 (0.52–1.37) |
≥75 | 3/324 | 4/189 | 0.63 (0.14–2.85) | 0.88 (0.37–2.08) |
Gender | ||||
Male | 42/3183 | 50/2039 | 0.69 (0.45–1.04) | 0.73 (0.49–1.08) |
Female | 18/2664 | 12/1573 | 1.22 (0.58–2.55) | 1.27 (0.68–2.36) |
Race | Â | Â | Â | Â |
White | 46/3405 | 49/2190 | 0.78 (0.52–1.17) | 0.83 (0.56–1.23) |
Black | 4/215 | 1/200 | 3.92 (0.44–35.08) | 1.50 (0.55–4.11) |
Asian | 10/2227 | 12/1222 | 0.59 (0.25–1.37) | 0.76 (0.39–1.49) |
Use of rescue medication | ||||
No | 43/5080 | 46/2824 | 0.70 (0.46–1.07) | 0.75 (0.50–1.12) |
Yes | 17/767 | 16/788 | 1.10 (0.56–2.19) | 1.11 (0.64–1.91) |
Investigator-reported hypoglycemia | ||||
No | 48/5197 | 37/2918 | 0.86 (0.56–1.32) | 0.97 (0.65–1.45) |
Yes | 12/650 | 25/694 | 0.79 (0.39–1.59) | 0.78 (0.41–1.47) |
Framingham 10-year CV risk score | ||||
≤15% | 20/3797 | 24/2438 | 0.65 (0.36–1.18) | 0.76 (0.45–1.29) |
>15% | 36/1433 | 38/1046 | 0.85 (0.54–1.35) | 0.91 (0.60–1.39) |
Baseline microalbuminuria | ||||
Normal (≤30 mg/g) | 25/3610 | 25/2389 | 0.84 (0.48–1.47) | 0.91 (0.56–1.50) |
Elevated (>30 to ≤300 mg/g) | 21/1248 | 21/771 | 0.75 (0.41–1.38) | 0.83 (0.49–1.41) |
High (>300 mg/g) | 6/280 | 14/241 | 0.43 (0.16–1.11) | 0.63 (0.31–1.26) |